IRCT20151128025265N3招募中未知
Comparison of the effect of 4 weeks of caping and kinesiotype on reducing the symptoms of carpal tunnel syndrome during pregnancy (ultrasonography)
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 years 至 35 years（—）
- 性别
- Female
入选标准
- •The subjects are in the third trimester of pregnancy
- •The subjects are in the age range of 20 to 35 years
- •Dominant hand with carpal tunnel syndrome
- •Ultrasonographic findings should be positive in all subjects (increase in median cross-sectional area of ??more than 9 mm2)
排除标准
- •History of trauma to the median nerve or wrist such as bruises, fractures
- •Pre-pregnancy test takers have CTS
- •Multiple births
- •Skin sensitivity to kinesiotype in some subjects
- •Rheumatoid Arthritis
- •Hypothyroidism
- •Premature delivery of a volunteer
- •Discontinue patient cooperation
- •Irregularities in referrals
研究者
相似试验
已完成
不适用
Comparison of the effectiveness between 4 weeks and 8 weeks treatment of lansoprazole in iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissectioDiseases of the digestive systemKCT0000488Chung-Ang Univerisity Hospital74
进行中（未招募）
1 期
Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trialThe Active substance of Osteopor is Ossein Hydroxyapatite.Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis.MedDRA version: 9.1Level: LLTClassification code 10006956Term: Calcium deficiencyEUCTR2008-002280-14-FRPierre Fabre Médicament58
进行中（未招募）
不适用
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA.A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 8.1Level: PTClassification code 10003553Term: AsthmaEUCTR2006-005689-38-HUChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA. A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 14.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2006-005689-38-GBChiesi Farmaceutici S.p.A.240
进行中（未招募）
1 期
EVALUATION OF THE EFFECT OF 4 WEEKS TREATMENT WITH CHF 4226 pMDI 2µg DOSE GIVEN ONCE DAILY IN THE EVENING ON 24-HOUR TROUGH FEV1 IN ADULT AND ADOLESCENT PATIENTS AGED 15 YEARS OR OVER WITH MODERATE OR SEVERE PERSISTANT ASTHMA.A MULTICENTER, DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PARALLEL GROUP, PLACEBO AND ACTIVE (FORMOTEROL 12µg B.I.D.) CONTROLLED, EFFICACY, SAFETY AND TOLERABILITY STUDY.Persistent asthmaMedDRA version: 8.1Level: PTClassification code 10003553Term: AsthmaEUCTR2006-005689-38-BGChiesi Farmaceutici S.p.A.240